Citigroup Inc Rain Therapeutics Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.84 - $1.22 $1,964 - $2,853	2,339 Added 954.69%	2,584 $3,000
Q3 2023 Nov 09, 2023	SELL	$0.82 - $1.42 $3,990 - $6,909	-4,866 Reduced 95.21%	245 $0
Q2 2023 Aug 10, 2023	SELL	$1.09 - $9.93 $38,837 - $353,815	-35,631 Reduced 87.46%	5,111 $6,000
Q1 2023 May 11, 2023	BUY	$7.77 - $12.47 $107,101 - $171,886	13,784 Added 51.13%	40,742 $356,000
Q4 2022 Feb 09, 2023	BUY	$5.52 - $8.48 $147,571 - $226,704	26,734 Added 11934.82%	26,958 $215,000
Q3 2022 Nov 10, 2022	SELL	$4.75 - $8.01 $1,021 - $1,722	-215 Reduced 48.97%	224 $1,000
Q2 2022 Aug 10, 2022	SELL	$2.21 - $5.56 $1,851 - $4,659	-838 Reduced 65.62%	439 $2,000
Q1 2022 May 12, 2022	SELL	$5.07 - $13.68 $21,775 - $58,755	-4,295 Reduced 77.08%	1,277 $6,000
Q4 2021 Feb 10, 2022	BUY	$11.91 - $17.0 $55,988 - $79,917	4,701 Added 539.72%	5,572 $72,000
Q3 2021 Nov 10, 2021	BUY	$13.21 - $20.91 $11,505 - $18,212	871 New	871 $13,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.